SCHEMBL67727

SCHEMBL67727

COc1cc(-c2[nH]c(-c3ccc(F)cc3)nc2-c2ccnc(N[C@H]3CCN(S(C)(=O)=O)C3)n2)cnc1N

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 10/20 0.48
CCND1 P24385 10/20 0.48
CDK1 P06493 9/20 0.48
CDK2 P24941 9/20 0.48
IKBKB O14920 4/20 0.43
CDK9 P50750 3/20 0.41
CDK6 Q00534 2/20 0.41
CASK O14936 1/20 0.41
ROCK2 O75116 1/20 0.41
CDKL5 O76039 1/20 0.41
STK10 O94804 1/20 0.41
CDK14 O94921 1/20 0.41
ABL1 P00519 1/20 0.41
EGFR P00533 1/20 0.41
MAK P20794 1/20 0.41
CDK11B P21127 1/20 0.41
TTK P33981 1/20 0.41
CLK1 P49759 1/20 0.41
CLK2 P49760 1/20 0.41
CLK3 P49761 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL69453 1.00 CDK4 (0.48) CDK4CCND1CDK1CDK2IKBKB
SCHEMBL67728 1.00 CDK4 (0.48) CDK4CCND1CDK1CDK2IKBKB
SCHEMBL87859 0.91 CDK2 (0.45) CDK4CCND1CDK1CDK2IKBKB
SCHEMBL69402 0.88 CDK2 (0.47) CDK4CCND1CDK1CDK2CDK9
SCHEMBL68689 0.88 CDK2 (0.47) CDK4CCND1CDK1CDK2CDK9
SCHEMBL68690 0.88 CDK2 (0.47) CDK4CCND1CDK1CDK2CDK9
SCHEMBL84214 0.86 CDK4 (0.40) CDK4CCND1CDK1CDK2TTK
SCHEMBL69317 0.86 EIF2AK2 (0.43) CDK4CCND1CDK1CDK2CLK2
SCHEMBL68164 0.85 MAPK14 (0.44) CDK4CCND1CDK1CDK2MAPK8
SCHEMBL87624 0.83 MAP3K11 (0.37) CDK4CCND1CDK1CDK2BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865732-B2 Heterocyclic compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 US disclosed
US-8865732-B2 Heterocyclic compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 US disclosed
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof NOVARTIS AG (CH) 2013-08-15 US disclosed
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof NOVARTIS AG (CH) 2013-08-15 US disclosed
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS CDK4 12/4885CCND1 747/4885CDK1 53/4885
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof BRAF, RAF1, HRAS CDK4 20/4885CCND1 919/4885CDK1 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.